People on the Move
Armetheon
Armetheon, a small molecule cardio drugmaker, has appointed Andrew Lam as VP of Product Development.
Lam has over 27 years of experience in pharma, working with regulators in the US, EU, Japan and China. At Armetheon, he will lead chemistry, manufacturing, and controls development and pharmaceutical operations.
The company’s oral anticoagulant tecarfarin is in late stage clinical trials.
"Andrew has an impressive track record in delivering results throughout the development chain in large pharmaceutical companies, as well as early stage biotech companies, from drug design and formulation through scale-up manufacturing and commercialization.
“We believe his skills and insights will be critical as we progress our advanced-stage proprietary pipeline, including our lead candidate tecarfarin, currently in Phase 3 development to treat thrombosis," said Ken Kengatharan, President.
(Image: Rakka/Flickr/CC)
